Tokyo Tape
Sign in

ASKA Pharmaceutical Holdings

4886.TTSE PRIMEPharmaceutical
Key numbers · FY ended 2026-03
Revenue¥71.1bn+10.9% YoYOperating income¥5.8bn+9.4% YoYNet income (owners)¥5.4bn+6.3% YoYTotal assets¥112.4bn+7.8% YoYEPS (basic)¥191.12+6.2% YoY

Full financial history and reports →

Stock price4886 · View chart ↗

Open the price chart on TradingView.

Latest filings
Mon, May 25 · JST1 filing
15:32MATERIALASKA Pharmaceutical Holdings · Share transfer
Wed, Apr 8 · JST1 filing
15:335% STAKEASKA Pharmaceutical Holdings · Dalton Investments, Inc. + 2 joint holders · 20.49% → 21.32%+0.83pp
Tue, May 13 · JST1 filing
16:335% STAKEASKA Pharmaceutical Holdings · Dalton Investments, Inc. + 2 joint holders · 19.43% → 20.49%+1.06pp
Fri, Mar 28 · JST1 filing
15:315% STAKEASKA Pharmaceutical Holdings · Dalton Investments, Inc. + 2 joint holders · 17.94% → 19.43%+1.49pp
Wed, Mar 5 · JST1 filing
15:325% STAKEASKA Pharmaceutical Holdings · Dalton Investments, Inc. + 2 joint holders · 16.92% → 17.94%+1.02pp

All filings →

Major holders (5%+) · 2
HolderStakeChangeFiled
Dalton Investments, Inc.10.03%+0.73pp2026-04-08
NIPPON ACTIVE VALUE FUND PLC8.34%0.00pp2026-04-08

Each holder's own ratio from its most recent large-shareholding report.